The recommended starting dose of Wikijet is 2.5 mg injected subcutaneously once weekly for 4 weeks. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control. After 4 weeks on the 2.5 mg dose, the dose is increased to 5 mg once weekly. If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. The maximum recommended dosage is 15 mg once weekly. Wikijet is administered once
weekly, on the same day each week, at any time of the day, with or without meals. Wikijet is to be injected subcutaneously in the abdomen, thigh, or in the upper arm. The day of weekly administration can be changed if necessary as long as the time between two doses is at least 3 days (72 hours).

Tirzepatide is contraindicated in patients with known hypersensitivity to Tirzepatide or to any of the components. Also contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed. Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary. Hypersensitivity Reactions: Hypersensitivity reactions have been reported. Discontinue Tirzepatide if suspected. Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions. Severe Gastrointestinal Disease: Use of tirzepatide may be associated with gastrointestinal adverse reactions, sometimes severe. Tirzepatide has not been studied in patients with severe gastrointestinal disease and is not recommended in these patients. Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Patients with a history of diabetic retinopathy should be monitored. Risk of Thyroid C-cell Tumors.

Sometimes hypoglycemia can occur when used with sulfonylurea. The most frequent adverse reactions are gastrointestinal disorders, nausea, diarrhea, vomiting, abdominal pain, and constipation. Besides these injection site reactions may occur.

Oral Medications: Tirzepatide causes a delay of gastric emptying, and thereby has the potential to impact the absorption of other oral medications.

Pregnancy: Tirzepatide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Advise females using oral contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and 4 weeks after each dose escalation.
Lactation: There are no data on the presence of Tirzepatide in human milk, the effects on the breastfed infant, or the effects on milk production.
Pediatric Use: The safety and efficacy of Tirzepatide have not been established in pediatric patients (younger than 18 years).
Hepatic Impairment: No dose adjustment of Tirzepatide is recommended for patients with hepatic impairment.
Renal Impairment: No dose adjustment of Tirzepatide is recommended for patients with renal impairment.

Wikijet 2.5 mg/0.5 ml solution for injection in pre-filled syringe: Each box contains 1 pre-filled syringe of Tirzepatide 2.5 mg/0.5 ml injection.
Wikijet 5 mg/0.5 ml solution for injection in pre-filled syringe: Each box contains 1 pre-filled syringe of Tirzepatide 5 mg/0.5 ml injection.